Exelixis Inc

Financials

営業活動によるキャッシュフロー 333.51 M 884.27 M 投資活動によるキャッシュフロー 27.24 M 350.44 M 財務活動によるキャッシュフロー -254.57 M -969.59 M フリーキャッシュフロー 332.36 M 875.84 M

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

EXEL

Financials

Exelixis Inc

ニュース

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Exelixis (EXEL) Down 2.8% Since Last Earnings Report: Can It Rebound?

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Exelixis, Inc. (EXEL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

エクセリクシス、バークレイズ・ヘルスケア会議で戦略的成長とパイプラインの見通しを提示

Exelixis at Barclays Healthcare: Strategic Growth and Pipeline Insights

エクセリクシス、リアリンク・グローバル・ヘルスケア・カンファレンスでRCCとCRCの戦略的見解を提示

Exelixis at Leerink Global Healthcare Conference: Strategic Insights in RCC and CRC

Exelixis, Inc. (EXEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Exelixis at TD Cowen: Strategic Vision and Growth

エクセリクシス株、競合メルク・アンド・カンパニーの治験で優れた結果が示され下落

Exelixis stock falls after rival Merck trial shows better results